Role Of The LIM-only Protein LMO4 In Lung Development And Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$490,395.00
Summary
Lung cancer is the leading cause of death in cancer patients in Australia. Although treatments have improved in the past 10 years, new therapeutic strategies are eagerly awaited. Deregulation of molecules driving development of normal tissue is often observed in cancer. Our aim is to identify key regulators of lung development and lung repair after injury. We aim to evaluate the role of these molecules in the initiation and progression of lung cancer to identify new targets for therapies.
Resetting The Tipping Point: Converting Immune Checkpoint Non-responders Into Responders.
Funder
National Health and Medical Research Council
Funding Amount
$455,135.00
Summary
Although immunotherapy has recently shown a breakthrough in the treatment of lung cancers, with long-term full regression of the cancer in some patients, most patients unfortunately do not respond. In this proposal, we want to characterise the events that occur in a cancer that is cured by immunotherapy, while it regresses. By subsequently reinforcing those processes, we aim to tip the balance towards a response, thereby increasing the cure rate.
Low Dose Computed Tomography (LDCT) To Diagnose Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$3,032,884.00
Summary
This study aims to examine strategies for improving the effectiveness of lung cancer screening for reducing lung cancer deaths, and reducing the burden of the disease in the community. We will test the use of CT screening combined with a package of diagnostic measures, including the US NLST criteria, to determine if lung cancer nodules can be reliably detected at an earlier stage. Our aim in early detection is to also improve the potential for effective treatment approaches and health outcomes.
Mechanisms Of Hedgehog Signaling In Small Cell Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$439,564.00
Summary
Some types of lung are very sensitive to chemotherapy, however they frequently relapse, at which time they become resistant to this form of treatment. This project investigates how embryonic signaling pathways, that normally function to regulate organ formation in development, are activated and promote tumor regrowth following chemotherapy for lung cancer.
The Impact Of Therapy On T-cell Recognition Of Mutated Tumour Neo-antigens
Funder
National Health and Medical Research Council
Funding Amount
$1,126,685.00
Summary
Cancer is caused by mutations which should be 'seen' and destroyed by the patients immune cells, similar to how immune cells protect us against viruses. But they don't. This grant will study how current cancer treatments help the immune cells 'see' these mutations. We will undertake these studies in the important cancers lung cancer and mesothelioma.
Tumours secrete factors which are contained in specific structures called exosomes, and are used to prepare other organs of the body for subsequently incoming tumour cells, thereby facilitating the often mortal spread of the cancer. This project will investigate the way exosomes alter organs before tumour cells arrive, the composition of these exosomes in lung cancer patients and if they are novel markers for diseases progression as well as therapeutic intervention.
Cancer Radiotherapy 2020: Accounting For Tumour Deformation In Real Time To Improve Treatment Outcome
Funder
National Health and Medical Research Council
Funding Amount
$371,616.00
Summary
Tumours in lung and prostate cancer change shape during radiotherapy treatment. This is not accounted for in current care, compromising the therapeutic efficacy. We will develop the first radiotherapy system that can adjust the radiation beam in real time to follow the changing tumour shape. We will assess the performance of the system and quantify the clinical benefit. It is expected that clinical implementation of this technique will improve the cure rates and decrease the treatment toxicity.
NITRO: A Randomised Phase 3 Trial Of Adding Nitroglycerin To First Line Chemotherapy For Advanced Non-small Cell Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$504,960.00
Summary
Preliminary studies suggest that nitroglycerin paste can substantially improve the results of chemotherapy for advanced lung cancer. NITRO is a definitive, large-scale, randomised trial that is needed to reliably determine if these promising results are true, and worthy of widespread application in routine clinical practice.
Novel Surgery-chemotherapy-immunotherapy Approaches For Lung Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$662,819.00
Summary
Many patients undergo cancer surgery every year yet still die of cancer over the next few years because the surgeon couldnt remove all of the cancer cells, many of which were undetectable at the time of surgery. This grant will develop ways of combining chemotherapy drugs with immune therapy to 'mop up' hidden residual cancer cells after operations - the immune system, when stimulated appropriately, should be able to 'seek and destroy' those hidden deposits and thus cure these cancers.
Identification Of Interleukin-6 Trans-signalling As A Novel Target For Therapeutic Approaches To Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$627,089.00
Summary
Interleukin-6 (IL-6) has been implicated as a causative factor in lung cancer, the most lethal cancer worldwide, albeit by unknown mechanisms. Since IL-6 is also important for immune system homeostasis, the development of anti-IL-6 therapies requires an intimate knowledge of pathological versus physiological IL-6 signalling pathways. This project aims for the first time to define an alternative IL-6 signalling pathway, termed “trans signalling”, in the molecular pathogenesis of lung cancer.